Shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $1.74 and last traded at $1.64, with a volume of 5124401 shares trading hands. The stock had previously closed at $1.55.
Several analysts have recently issued reports on PTN shares. Zacks Investment Research raised shares of Palatin Technologies from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Friday, February 15th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $2.75 price objective on shares of Palatin Technologies in a research note on Sunday, May 12th. HC Wainwright boosted their price objective on shares of Palatin Technologies from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, TheStreet cut shares of Palatin Technologies from a “c-” rating to a “d” rating in a research note on Tuesday, February 19th.
Palatin Technologies (NYSEAMERICAN:PTN) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01).
WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2019/05/18/palatin-technologies-ptn-sets-new-52-week-high-at-1-74.html.
About Palatin Technologies (NYSEAMERICAN:PTN)
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
See Also: Are analyst ratings accurate?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.